Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?

We analyzed the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI). We retrospectively collected data from 16 worldwide centers involved in the treatment of RCC. Overall survival (OS) and progression-free survival (...

Full description

Bibliographic Details
Main Authors:	Matteo Santoni, Francesco Massari, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Ugo De Giorgi, Umberto Basso, Gaetano Aurilio, Lorena Incorvaia, Angelo Martignetti, Mimma Rizzo, Giacomo Cartenì, Enrique Grande, Marc R. Matrana, Simon J. Crabb, Nuno Vau, Giulia Sorgentoni, Alessia Cimadamore, Rodolfo Montironi, Nicola Battelli
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Series:	Diagnostics
Subjects:	body mass index cabozantinib obesity prognosis real-world data renal cell carcinoma
Online Access:	https://www.mdpi.com/2075-4418/11/1/138

Similar Items

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
by: Matteo Santoni, et al.
Published: (2019-12-01)

Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
by: Michael H. Storandt, et al.
Published: (2022-10-01)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
by: Rupesh Kotecha, et al.
Published: (2021-04-01)

Antitumor Effect of Cabozantinib in Bone Metastatic Models of Renal Cell Carcinoma
by: Michele Iuliani, et al.
Published: (2021-08-01)

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
by: Rathi N, et al.
Published: (2020-05-01)

Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
by: Anastasia A. Sachkova, et al.
Published: (2022-12-01)

Local Liver Irradiation Concurrently Versus Sequentially with Cabozantinib on the Pharmacokinetics and Biodistribution in Rats
by: Yu-Chuen Huang, et al.
Published: (2023-03-01)

The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
by: Jeffrey Sum-Lung Wong, et al.
Published: (2021-04-01)

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature
by: Minas P. Economides, et al.
Published: (2020-11-01)

Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with Unresectable Hepatocellular Carcinoma
by: Hironao Okubo, et al.
Published: (2022-11-01)

Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
by: Francesco Tovoli, et al.
Published: (2021-06-01)

Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers
by: Igor Richter, et al.
Published: (2022-03-01)

Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: A case report and review of the literature
by: Jacopo Lolli, et al.
Published: (2023-03-01)

Corrigendum: Impressive reduction of brain metastasis radionecrosis after cabozantinib therapy in metastatic renal carcinoma: a case report and review of the literature
by: Jacopo Lolli, et al.
Published: (2023-09-01)

RET-mutated recurrent leiomyosarcoma treated with cabozantinib: a case report
by: Carlos E. Salazar-Mejía, et al.
Published: (2023-07-01)

Cabozantinib as the causative agent of high-grade fever in a patient with a background of metastatic clear cell renal cell carcinoma: a case report
by: H. M. N. Chen, et al.
Published: (2020-11-01)

Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models
by: Shanshan Deng, et al.
Published: (2021-10-01)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
by: Bersanelli M, et al.
Published: (2018-09-01)

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
by: Iaxx R, et al.
Published: (2022-06-01)

Cabozantinib and IL-27 combinatorial therapy for bone-metastatic prostate cancer
by: Shreya Kumar, et al.
Published: (2023-09-01)

Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study
by: Maria I. Volkova, et al.
Published: (2023-08-01)

Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
by: Lorenza Rimassa, et al.
Published: (2021-12-01)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
by: Grassi P, et al.
Published: (2016-07-01)

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma
by: Emeline Colomba, et al.
Published: (2022-10-01)

Efficacy of cabozantinib therapy for brain metastases from renal cell carcinoma
by: Takashi Nakagawa, et al.
Published: (2022-07-01)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
by: Thomas Powles, et al.
Published: (2021-08-01)

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
by: Sharon Del Vecchio, et al.
Published: (2018-10-01)

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
by: Balázs Jóri, et al.
Published: (2023-09-01)

Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
by: Maximilian Sieg, et al.
Published: (2020-04-01)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
by: Hao Wang, et al.
Published: (2022-09-01)

Anti-tumor activity of cabozantinib by FAK down-regulation in human oral squamous cell carcinoma
by: Da-Lu Li, et al.
Published: (2015-12-01)

Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies
by: Khalid Alhazzani, et al.
Published: (2023-10-01)

Multimodality imaging approach in a case of vascular toxicity caused by cabozantinib
by: Georgios Benetos, MD, FESC, et al.
Published: (2024-01-01)

Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
by: Debaillon Vesque A, et al.
Published: (2020-06-01)

Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child–Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial
by: Anthony B. El-Khoueiry, et al.
Published: (2022-04-01)

Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy
by: Cierra Hong, et al.
Published: (2021-03-01)

Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma treated with cabozantinib and nivolumab
by: Carlos Eduardo Salazar-Mejía, et al.
Published: (2020-12-01)

Cannabidiol Enhances Cabozantinib-Induced Apoptotic Cell Death via Phosphorylation of p53 Regulated by ER Stress in Hepatocellular Carcinoma
by: Youngsic Jeon, et al.
Published: (2023-08-01)

Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib, regorafenib, and ramucirumab
by: Andrea S. Fung, et al.
Published: (2020-07-01)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
by: Bo Shi, et al.
Published: (2022-06-01)